Intermittent Claudication Clinical Trial
Official title:
Cross-sectoral Rehabilitation for Patients With Intermittent Claudication: Effects and Patient Experience - The CIPIC-Rehab Study (Cross-sectoral Intervention for Patients With Intermittent Claudication)
Verified date | November 2018 |
Source | Rigshospitalet, Denmark |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Exercise training combined with other lifestyle changes are essential elements in
conservative management of patients with Intermittent Claudication (IC). IC is essentially
caused by atherosclerosis, which reduces blood flow to the legs and leads to cramping leg
pain when walking. Patients suffering from IC may have difficulty in exercising and changing
lifestyle without systematic intervention despite the risk of morbidity, mortality and
hospitalization. Today, rehabilitation programs, including supervised exercise, exist for
patients suffering ischemic heart disease but not for patients with IC, despite evidence that
exercise therapy is highly beneficial for patients suffering IC.
The overall aim of the present study is to examine the effect of conservative management of
patients with IC provided as a three month, cross-sectoral exercise and lifestyle
intervention program based on the already established cardiac rehabilitation program. Outcome
will be assessed on walking distance and secondly on lifestyle changes and patient reported
outcomes.
Implications:
The project will provide evidence for the effect of cross-sectoral collaborative conservative
management of patients with IC, using the existing rehabilitation program already offered to
patients suffering ischemic heart disease. Moreover, it will elicit knowledge on patient
perceptions of conservative management of IC provided as a proactive cross-sectoral
intervention and ways to support patients with IC in adhering to conservative management.
Status | Enrolling by invitation |
Enrollment | 118 |
Est. completion date | September 2020 |
Est. primary completion date | June 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Patients with newly diagnosed Intermittent Claudication, referred to dept. of vascular surgery and offered conservative management. - Citizens in the municipalities of the study. - Able to understand, read and speak Danish. - Able to perform physical exercise and informed consent to participate in the trial. Exclusion Criteria: - Patients that needs vascular surgery. - Co-morbidity that hinder participation and to perform physical exercise. |
Country | Name | City | State |
---|---|---|---|
Denmark | Dept. of Vascular Surgery, Rigshospitalet, University of Copenhagen. | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum Walking Distance on a treadmill | Change from Baseline Maximum Walking Distance at 12 months. Detect an improvement of 60 meters in Maximum Walking Distance in the intervention group compared to the control group, using the standardized Treadmill Walking Test. | 12 months | |
Secondary | Pain-free walking distance on a treadmill | Change of Pain-free walking distance (PWD) in meters, measured using the standardized Treadmill Walking Test compared to the control group. | 12 months | |
Secondary | Quality of Life Measurement | Quality of Life questionnaire (VascuQol). Change from Baseline score at 12 months compared to the control group. 6 questions - level of pain, walking capacity and social activity associated with Intermittent claudication. | 12 months | |
Secondary | Depression and anxiety Measurement | Hospital Anxiety and Depression Scale (HADS).Change from Baseline score at 12 months. Score 0-21. Lowest possible score is better. | 12 months | |
Secondary | Self-management Measurement | The Patient Activation Measure (PAM13).Change from Baseline score at 12 months. More or less activation compared to the control group. More activation is better. | 12 months | |
Secondary | smoking cessation Measurement | Change from Baseline score at 12 months.Smoking cessation or not. | 12 months | |
Secondary | Daily physical activity Measurement | Change from Baseline score at 12 months. More or less active. Minimum 30 min. walking daily. | 12 months | |
Secondary | Diet Registration Measurement | Change from Baseline score at 12 months. More or less healthy diet. Healthy diet score change to a higher percentage where 75% is healthy diet. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400395 -
Clinical Trial for GNX80 in Intermittent Claudication
|
Phase 4 | |
Active, not recruiting |
NCT02341716 -
Hospital- and Home-based Supervised Exercise Versus UNsupervised Walk Advice For Patients With InTermittent Claudication
|
N/A | |
Completed |
NCT02041169 -
Lower Extremity Peripheral Arterial Disease and Exercise Ischemia
|
N/A | |
Completed |
NCT00822172 -
Evaluation of Cilostazol in Combination With L-Carnitine
|
Phase 4 | |
Recruiting |
NCT00538408 -
Whole Body Magnetic Resonance Angiography in Ischemic Patients
|
N/A | |
Completed |
NCT00388128 -
Caffeine and Intermittent Claudication
|
Phase 3 | |
Completed |
NCT00618670 -
Home-based vs. Supervised Exercise for People With Claudication
|
N/A | |
Recruiting |
NCT00146666 -
Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)
|
Phase 2 | |
Completed |
NCT00134277 -
Trial Comparing Different Medical Devices for Infragenual Dilatation
|
N/A | |
Completed |
NCT01256775 -
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
|
Phase 2 | |
Completed |
NCT00029991 -
Extract of Ginkgo Biloba (EGB 761) and Vascular Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06299956 -
Supervised Exercise-based Rehabilitation for People With Intermittent Claudication in Denmark
|
N/A | |
Not yet recruiting |
NCT05335161 -
A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease
|
Phase 1 | |
Completed |
NCT04390282 -
Secondary Prevention and Application-based Lifestyle Support for Patients With Intermittent Claudication
|
N/A | |
Completed |
NCT03271710 -
Study to Evaluate the Lower Extremity Intervention With Integrated Embolic Protection Using the Vanguard IEP System
|
N/A | |
Completed |
NCT02380794 -
Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule
|
Phase 2 | |
Active, not recruiting |
NCT02276937 -
Randomized Phase IIb Trial of DVC1-0101
|
Phase 2 | |
Completed |
NCT02097082 -
Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System
|
N/A | |
Recruiting |
NCT00539266 -
Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia
|
Phase 2/Phase 3 | |
Completed |
NCT00071266 -
The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
|
Phase 3 |